Vadodara - Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June, 2023.

Financial Highlights

Net Sales grew 18% to Rs.1486 crores for the quarter.

Net Profit for the quarter at Rs.121 crores.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said 'The company grew in all the business segments with India outperforming the market with 9% growth, Ex US generics grew 46%, API grew 31% and the US generics business grew 6%. We have also started commercializing products from our Oncology and Injectable Facilities'

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5000 are well recognized by doctors and patients.

Contact:

Ajay Kumar Desai

Tel: +91 022- 66953681

Email: ajay.desai@alembic.co.in

(C) 2023 Electronic News Publishing, source ENP Newswire